The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date.

4 trials

Sponsors

Neurocrine Biosciences (United States), Lundbeck (Denmark), PharmaMar (Spain), AstraZeneca (Sweden)

Conditions

The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date. Other

Phase 1

Phase I study of PM534 to patients with advanced solid tumors

RecruitingISRCTN97337444

PharmaMar (Spain)The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date. Other

Start: 2026-04-10Target: 15Updated: 2026-06-01

Deferred registration: Phase I Trial: MAC code 'MAC215'

RecruitingISRCTN10994097

Neurocrine Biosciences (United States)The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date. Other

Start: 2026-05-22Target: 30Updated: 2026-06-29

Deferred registration: Fortrea code: 780587

RecruitingISRCTN17866568

Lundbeck (Denmark)The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date. Other

Start: 2026-07-08Target: 15Updated: 2026-07-20

Phase 2

Deferred registration - AstraZeneca/United Kingdom Code: D7260C00014

Active, not recruitingISRCTN99796543

AstraZeneca (Sweden)The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date. Other

Start: 2027-05-03Target: 100Updated: 2026-09-14